Owlstone Medical 获得 $27M 以推进用于早期疾病检测的呼吸分析技术。 Owlstone Medical secures $27M to advance breath-analysis tech for early disease detection.

Owlstone Medical 是一家专门从事呼吸疾病检测的英国公司，在最近由 Ventura Capital 领投的一轮融资中筹集了 2700 万美元。 Owlstone Medical, a UK firm specializing in breath-based disease detection, has raised $27 million in a recent funding round led by Ventura Capital. 该公司计划利用这些资金开发其呼吸系统生物心理平台,并启动肺癌和肝病等疾病的新诊断测试。 The company plans to use the funds to develop its Breath Biopsy® platform and to launch new diagnostic tests for diseases like lung cancer and liver disease. 该技术旨在提供非侵入性和早期疾病探测,以取得更好的患者结果。 The technology aims to offer non-invasive and early disease detection for better patient outcomes.

文章

FinSMEs

zenopa.com

www.businessweekly.co.uk

pharmatimes.com

-- 显示更少 --

相关故事